Sumitomo Mitsui Trust Group Inc. Sells 890 Shares of DaVita Inc. (NYSE:DVA)

Sumitomo Mitsui Trust Group Inc. reduced its stake in DaVita Inc. (NYSE:DVA) by 0.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,099 shares of the company’s stock after selling 890 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.14% of DaVita worth $16,689,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in DVA. Epoch Investment Partners Inc. bought a new position in shares of DaVita in the fourth quarter worth $55,100,000. Invesco Ltd. boosted its holdings in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after acquiring an additional 275,284 shares during the period. Iron Triangle Partners LP bought a new position in shares of DaVita in the fourth quarter worth $38,946,000. Amundi raised its position in shares of DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in DaVita by 14,695.8% during the first quarter. GAMMA Investing LLC now owns 234,809 shares of the company’s stock valued at $35,919,000 after buying an additional 233,222 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

NYSE:DVA opened at $142.56 on Friday. The stock has a fifty day moving average of $140.00 and a 200 day moving average of $149.27. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. The firm has a market capitalization of $10.76 billion, a price-to-earnings ratio of 14.13, a P/E/G ratio of 0.98 and a beta of 1.11.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same quarter last year, the business posted $2.26 earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Ratings Changes

DVA has been the subject of several research analyst reports. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Truist Financial dropped their price objective on DaVita from $170.00 to $164.00 and set a “hold” rating for the company in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.